- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.01. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 28.01. | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress | 387 | GlobeNewswire (Europe) | SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| 13.01. | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics' new year update and seeks shareholders' feedback on proposal to improve shareholder value for their patient capital | 346 | GlobeNewswire (Europe) | SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| 13.01. | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 08.12.25 | CytoMed: Partnerschaft für klinische Studie in Malaysia treibt Aktie an | 1 | Investing.com Deutsch | ||
| 08.12.25 | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology ... | 123 | GlobeNewswire (Europe) | SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| CYTOMED THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.12.25 | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 18.11.25 | CytoMed acquires TC BioPharm's gamma delta T cell technology | 1 | Investing.com | ||
| 18.11.25 | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India | 687 | GlobeNewswire (Europe) | SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| 18.11.25 | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.11.25 | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 22.10.25 | CytoMed Therapeutics' chairman increases effective holdings to 21.95% | 1 | Seeking Alpha | ||
| 22.10.25 | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics' Chairman Increases Effective Holdings to 21.95% | 1 | GlobeNewswire (USA) | ||
| 22.10.25 | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 14.10.25 | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 02.10.25 | CytoMed reports promising preclinical results for leukemia treatment | 1 | Investing.com | ||
| 02.10.25 | CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center | 2 | GlobeNewswire (USA) | ||
| 30.09.25 | CytoMed Therapeutics Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 28.08.25 | CYTOMED THERAPEUTICS LIMITED: Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition | 427 | GlobeNewswire (Europe) | SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing... ► Artikel lesen | |
| 21.07.25 | CYTOMED THERAPEUTICS LIMITED: Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or ... | 239 | GlobeNewswire (Europe) | SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,725 | +0,81 % | flatexDEGIRO, Qiagen, Börse München - 4investors-Weekend | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Und welche Titel haben besonders starke Kursbewegungen verzeichnet? Vor allem für Trader ist es wichtig zu wissen... ► Artikel lesen | |
| BIONTECH | 92,10 | -1,29 % | Aufgrund von angeblichen Patentverletzungen zieht BioNTech gegen Moderna vor Gericht | Die Hersteller von Corona-Impfstoffen haben sich schon seit Jahren in den Haaren. Immer wieder gibt es Vorwürfe über Patentverletzungen. So auch in einem aktuellen Fall, bei dem BioNTech gegen den US-Hersteller... ► Artikel lesen | |
| EVOTEC | 5,776 | -1,40 % | Evotec Aktie vor dem Durchbruch? Diesmal ist etwas anders... | Die Evotec Aktie hat zuletzt ein wichtiges Muster bestätigt: Wiederholt scheiterte die Biotech-Aktie aus Hamburg mit Breakversuchen an der 200-Tage-Linie. Nach mehr oder weniger starken Ausbrüchen hierüber... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 89,63 | -1,89 % | Morgan Stanley cuts Kymera Therapeutics stock price target on pipeline progress | ||
| APOGEE THERAPEUTICS | 70,03 | 0,00 % | Apogee Therapeutics reports FY results | ||
| CG ONCOLOGY | 58,80 | 0,00 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 17,740 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary .. | In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate... ► Artikel lesen | |
| KYVERNA THERAPEUTICS | 8,210 | 0,00 % | Kyverna Therapeutics, Inc.: Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors | Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization Andrew Miller adds deep clinical development and product approval... ► Artikel lesen | |
| BB BIOTECH | 51,60 | +0,39 % | BioNTech, Valneva oder BB Biotech: Warum es HIER in Kürze knallt! | Die Biotechbranche steht zu Beginn des Jahres 2026 erneut im Spannungsfeld zwischen wissenschaftlicher Innovation und wachsender Skepsis der Kapitalmärkte. Nach Jahren extremer Kursbewegungen prüfen... ► Artikel lesen | |
| MODERNA | 44,100 | -2,75 % | Moderna freut sich über eine Zulassungsempfehlung der EMA für einen Kombi-Impfstoff gegen Corona und Grippe | Bei Corona-Impfstoffen war der US-Konzern Moderna noch ein Nachzügler. Anders scheint es nun bei Kombi-Impfstoffen zu laufen, die gleichzeitig vor Corona und der Grippe schützen. Dafür gibt es bisher... ► Artikel lesen | |
| MBX BIOSCIENCES | 32,550 | 0,00 % | MBX Biosciences, Inc. - 8-K, Current Report | ||
| IMMUNITYBIO | 8,764 | +5,72 % | ImmunityBio, Inc.: ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally | 2025 Sales Momentum: ANKTIVA net product revenue increased 20% quarter-over-quarter, with full-year net product revenue of $113 million, representing an approximately 700% increase year-over-year... ► Artikel lesen | |
| TANGO THERAPEUTICS | 11,140 | 0,00 % | Stifel reiterates Tango Therapeutics stock rating at Buy | ||
| STRYKER | 327,70 | -0,09 % | Think Surgical announces first TMINI robot cases with Stryker knee implant | ||
| OCUGEN | 1,427 | -7,07 % | Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa | Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patientsTopline... ► Artikel lesen |
CYTOMED THERAPEUTICS LIMITED gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,01 % bei einem Aktienkurs von 0,760 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYTOMED THERAPEUTICS LIMITED finden Sie auf Wallstreet Online.